GenEng News  Jun 8  Comment 
SciClone Pharmaceuticals said today it agreed to be acquired for approximately $605 million by a consortium of Chinese investors, asserting that the deal would not only benefit shareholders but offered the best option for the company to continue...
Reuters  Nov 14  Comment 
* Gl Management And Its Affiliates submit proposal to board of Sciclone Pharmaceuticals Inc to buyout the Co at $11.18 per share in cash
Benzinga  Sep 29  Comment 
The Dow fell 0.04 percent to 18,331.23, while the NASDAQ composite index declined 0.37 percent to 5,298.79. The broader Standard & Poor's 500 index slipped 0.08 percent to 2,169.54. The worst performing industries in the market today...


SciClone Pharmaceuticals (NASDAQ: SCLN) is a global specialty pharmaceutical company that specializes in cancer and infectious diseases. The company makes money off its two in-licensed products that are part of its international commercial growth strategy. Though it claims itself as international, the company's core markets is in China where it has built a solid reputation through marketing ZADAXIN. With the Chinese pharmaceutical markets growing by annual growth rates of more than 20% annual over the next few years, SCLN hopes to leverage its brand name to secure a stronger foothold in the market.[1] SCLN believes it may do this through its sales organization of more than 200 medical representatives, of which they have developed a good reputation and relationship with over 500 hospitals in major cities of China.[2]

Business Growth

Since SCLN's 1996 launch of ZADAXIN in China, the medication reached worldwide sales of $85 million by 2010 in worldwide sales, 96% of which is coming from China. ZADAXIN is currently one of the largest imported pharmaceutical product in China by revenue, and its volume market share of thymalfasin is approximately 5%.[3] Going forward, China will still be an inseparable market place for SCLN, though it is headquartered in California.

China Remains an Important Market for SCLN

SCLN has an established business in China with growing product revenue and positive cash flow. SCLN continues to build this base and introduce additional pharmaceutical products. As China state leaders have agreed about a new health care reform plan which, among other things, is seeking to expand patient access to pharmaceuticals, SCLN will be able to capitalize on the growth going forward.

In China, orders for ZADAXIN for example are filed largely by distributors and sub distributors who purchase ZADAXIN from their selected, established, government-licensed importing agents. As China accounted for approximately 96% of total product sales, China will remain a very important target for SCLN.

Increased Support for Generics Wear Down SLCN's Profits

Traditionally, a pharmaceutical company such as SLCN makes money by investing heavily in R&D in hopes of a high payout. A blockbuster drug such as Lipitor for example can easily make over $1 billion in sales per year. Unfortunately, increased competition within generics as well as support for generics push down the profit margins. Usually, a branded drug's sales falls 80%, eaten up by generics competition, within the first year of patent expiration. Once these patents expire, generic companies receive the authorization to develop same or similar products that often dilute the market share of the first developer. Because the Food and Drug Administration (FDA) give special privileges to the first generic manufacturer to submit an application, called Abbreviated New Drug Application (ANDA), for approval in order to encourage the generics industry, generics are highly incentivized to rush into drug as soon as the medicine is off-patent. Unfortunately, this prompts extremely high competition which erodes the profitability quickly such that generics have a tougher time to sustain the same gross profit margins experienced by the same pharmaceuticals under patent.


Though OSIR operates in a niche segment, it still competes in the pharma sphere for drug applications and approvals. The company also feels pressure from generics as it must time its patent wisely. As such, OSIR's competitors include:


  1. FORMA Therapeutics Grants Genentech Exclusive Rights To Acquire A Pre-Clinical Cancer Program
  2. FY2010 Form 10-K SCLN, Pg 24
  3. FY2010 Form 10-K SCLN, Pg 45
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki